Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 9Neoplasm Metastasis 7Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Tongue Neoplasms 1Thymoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Neoplasms 1Hypoxia 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Gliosarcoma 1

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × NVP-BKM120 × Clear all
NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Novartis

Phase 1/2 Terminated
43 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡